Peter Biotherapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Peter Biotherapeutics is a private, preclinical-stage biotech founded in 2020, developing next-generation gene-editing therapies. Its flagship platform, RITDM™ 2.0, is a novel gene-editing technology that avoids creating double-strand DNA breaks and uses no bacterial or viral components, potentially offering a superior safety profile and enabling repeat dosing. The company is initially targeting genetic diseases such as metabolic disorders, sickle cell disease, and Duchenne Muscular Dystrophy, as well as oncology, leveraging a leadership team and scientific advisory board with deep expertise in genetics and drug development.

Genetic DiseasesOncology

Technology Platform

RITDM™ 2.0 (Recombination Induced Template-driven DNA Modification): A gene-editing platform that uses engineered fusion proteins to locally unwind DNA without creating double-strand breaks, avoiding bacterial/viral components to enable precise editing with a potentially improved safety profile and suitability for repeat dosing.

Opportunities

The primary opportunity lies in addressing the significant safety limitations of first-generation gene-editing technologies.

If clinically validated, RITDM™'s break-free, non-immunogenic profile could enable treatment for a wider range of chronic genetic diseases and allow for safer repeat dosing.

This positions PeterBio to capture value in large, validated markets like sickle cell disease and DMD, where safety and durability are paramount.

Risk Factors

Major risks include the unproven nature of the novel RITDM™ platform, which must demonstrate sufficient editing efficiency and its proposed safety advantages in rigorous preclinical and clinical testing.

The company also faces intense competition from well-funded rivals advancing alternative next-generation editing technologies and depends on continued venture financing to sustain operations.

Competitive Landscape

PeterBio competes in the crowded and rapidly evolving gene-editing therapeutics space. Direct competitors include public companies like Beam Therapeutics (base editing) and Prime Medicine (prime editing), which also aim to improve precision and safety over standard CRISPR. It also faces competition from established leaders like CRISPR Therapeutics and Intellia Therapeutics, which are advancing their own next-gen platforms. PeterBio's differentiation hinges on the unique, break-avoiding mechanism of RITDM™.

More companies in United States →